SUDEEPPHRM Share Price | Sudeep Pharma Ltd Stock Analysis & Recommendation

Q: Why is Sudeep Pharma Ltd falling/rising?

As of 05-Aug, Sudeep Pharma Ltd's stock price is rising, currently at 956.35, reflecting an increase of 86.9 or 9.99%. This upward movement is supported by several factors. The stock has outperformed the benchmark Sensex, with a 1-week return of +8.83% compared to the Sensex's +1.19%, and a 1-month return of +10.38% against the Sensex's +1.05%. Year-to-date, the stock has shown a remarkable increase of +58.74%, while the Sensex has declined by 7.79%.Today, the stock reached a new 52-week and all-time high of Rs. 956.35, indicating strong market interest. Despite opening with a loss of -6.08%, it has gained 10.11% over the last two days, demonstrating a positive trend. The stock's performance today has also outperformed its sector by 10.09%. Moreover, Sudeep Pharma is trading above its moving averages across various time frames, which is typically a bullish signal. However, it is important to note that there has been a decrease in investor participation, with delivery volume falling by -24.55% against the 5-day average, which could indicate some caution among investors. Nevertheless, the company's strong management efficiency and low debt to EBITDA ratio further support the stock's positive outlook. Overall, the combination of strong returns, new highs, and positive performance metrics contributes to the rising stock price of Sudeep Pharma Ltd.

Q: Are Sudeep Pharma Ltd latest results good or bad?

Sudeep Pharma Ltd's latest results present a mixed picture. On one hand, the company reported a net profit of ₹40.55 crores for Q1 FY27, which is a significant increase of 31.61% year-on-year. Additionally, the revenue grew by 26.70% compared to the same quarter last year, indicating strong market traction.However, there are concerns regarding the sequential performance. The net profit declined by 17.04% from the previous quarter, which raises questions about the sustainability of their growth. The operating margin also saw a slight contraction to 34.69%, down from 35.13% year-on-year, reflecting some cost pressures.Overall, while the year-on-year growth figures are encouraging, the quarter-on-quarter declines in both net profit and revenue suggest that the company may be facing challenges that need to be addressed. Investors should monitor these trends closely to gauge the company's future performance.

Q: Should I buy, sell or hold Sudeep Pharma Ltd?

Based on the current analysis of Sudeep Pharma Ltd, it would be advisable to hold your position in the company for now. The company demonstrates high management efficiency with a strong return on equity (ROE) of 19.6%, indicating effective management of shareholder funds. Additionally, it has a low debt to EBITDA ratio of 0.68 times, which suggests a solid ability to service its debt obligations.However, there are concerns regarding long-term growth, as the operating profit has stagnated with an annual growth rate of 0% over the past five years. Recent results also show a decline in profit after tax (PAT) for the latest quarter, which fell by 6.2% compared to the previous four-quarter average, despite a significant growth in interest.The valuation appears high with a price to book value of 12.2, and there has been a slight decrease in institutional investor participation, which can be a red flag since these investors typically have better insights into company fundamentals.Given these mixed signals, maintaining your current position seems prudent until there are clearer signs of growth or improvement in the company's performance.

Q: When is the next results date for Sudeep Pharma Ltd?

The next results date for Sudeep Pharma Ltd is scheduled for August 4, 2026.

Results Declared: Sudeep Pharma has declared results on 04 Aug 2026! Click here to unlock the latest financial performance

Dividend Alert: Sudeep Pharma Ltd has declared 150% dividend, ex-date: 23 Jul 26

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

6.78 lacs (-1.70%) Volume

Shareholding (Jun 2026)

FII

1.81%

Held by 17 FIIs

DII

15.64%

Held by 9 DIIs

Promoter

76.15%

Why is Sudeep Pharma Ltd falling/rising?

06-Aug-2026

As of 05-Aug, Sudeep Pharma Ltd's stock price is at 956.35, reflecting a significant increase of 9.99%. The stock has outperformed the Sensex and reached a new all-time high, supported by strong returns and positive performance metrics, despite a decrease in investor participation.

View full answer

Which are the latest news on Sudeep Pharma?

06-Aug-2026

Broad-Based Technical Strength Lifts Sudeep Pharma Ltd to 52-Week High of Rs 988.7
Sudeep Pharma Ltd Hits All-Time High of Rs 988.7 as Momentum Builds Across Timeframes

Are Sudeep Pharma Ltd latest results good or bad?

05-Aug-2026

Sudeep Pharma Ltd's latest results show strong year-on-year growth with a 31.61% increase in net profit and a 26.70% rise in revenue, but there are concerns due to a 17.04% decline in net profit from the previous quarter and slight contraction in operating margin, indicating potential challenges ahead. Investors should monitor these trends closely.

View full answer

Should I buy, sell or hold Sudeep Pharma Ltd?

05-Aug-2026

When is the next results date for Sudeep Pharma Ltd?

28-Jul-2026

The next results date for Sudeep Pharma Ltd is August 4, 2026.

View full answer

What does Sudeep Pharma do?

11-Jun-2026

Sudeep Pharma Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 182 Cr and a net profit of 49 Cr for the quarter ending March 2026. Key metrics include a P/E ratio of 48.00 and a market cap of INR 8,550 Cr.

View full answer

How big is Sudeep Pharma?

11-Jun-2026

As of 10th June, Sudeep Pharma Ltd has a market capitalization of 8,550.00 Cr, with recent net sales of 642.27 Cr and net profit of 172.90 Cr over the last four quarters.

View full answer

Who are the peers of the Sudeep Pharma?

11-Jun-2026

Sudeep Pharma's peers include Sanofi Consumer, P & G Health Ltd, Akums Drugs, Strides Pharma, Blue Jet Health, Supriya Lifesci., Sanofi India, SPARC, and FDC. Most peers show Below Average growth and management risk, with SPARC exhibiting Excellent growth, while Supriya Lifesci. has the highest 1-year return at 42.25% and Sanofi India the lowest at -48.76%.

View full answer

Compare Sudeep Pharma with Similar Stocks

Sanofi Consumer Orchid Pharma Akums Drugs

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Management Efficiency with a high ROE of 0%

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.68 times

Poor long term growth as Operating profit has grown by an annual rate 0% of over the last 5 years

Flat results in Jun 26

With ROE of 19.6, it has a Very Expensive valuation with a 12.5 Price to Book Value

Falling Participation by Institutional Investors

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 10,961 Cr (Small Cap)

P/E

60.00

Industry P/E

Dividend Yield

0.16%

Debt Equity

0.04

Return on Equity

19.57%

Price to Book

12.23

Revenue and Profits:

Net Sales:

158 Cr

(Quarterly Results - Jun 2026)

Net Profit:

41 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0.16%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

44.39%

0.23%

44.62%

6 Months

52.43%

0.23%

52.66%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Latest dividend: 1.5000000000000002 per share ex-dividend date: Jul-23-2026

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Broad-Based Technical Strength Lifts Sudeep Pharma Ltd to 52-Week High of Rs 988.7

With a decisive surge to Rs 988.7 on 6 Aug 2026, Sudeep Pharma Ltd has reached a fresh 52-week high, propelled by a confluence of bullish technical indicators and sustained price momentum over recent sessions.

Read full news article

Sudeep Pharma Ltd Hits All-Time High of Rs 988.7 as Momentum Builds Across Timeframes

Extending its winning streak to four sessions, Sudeep Pharma Ltd surged to a fresh all-time high of Rs 988.7 on 6 Aug 2026, outperforming both its sector and the broader market with a 1.45% gain on the day against the Sensex’s 0.31% rise.

Read full news article

Are Sudeep Pharma Ltd latest results good or bad?

Sudeep Pharma Ltd's latest financial results for Q1 FY27 present a mixed operational picture. The company reported a net profit of ₹40.55 crores, reflecting a year-on-year growth of 31.61% from ₹30.81 crores in Q1 FY26. However, this marks a sequential decline of 17.04% from the previous quarter's profit of ₹48.88 crores. The revenue for the quarter reached ₹158.27 crores, indicating a robust year-on-year growth of 26.70%, although it experienced a quarter-on-quarter decline of 13.20% from ₹182.34 crores in Q4 FY26. The operating margin for the quarter stood at 34.69%, a slight contraction from 35.13% in the same quarter last year. This margin compression, alongside a decline in the profit after tax (PAT) margin to 25.65% from 26.62% in Q4 FY26, suggests that the company is facing cost pressures that could impact its profitability moving forward. Sudeep Pharma's operational efficiency is highlighted by a ...

Read full news article

Announcements

No announcement available

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

Sudeep Pharma Ltd has declared 150% dividend, ex-date: 23 Jul 26

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

EBIT to Interest (avg)

33.98

Debt to EBITDA (avg)

0.72

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

0.65

Tax Ratio

23.58%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

17.46%

ROCE (avg)

24.88%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

12.45

EV to EBIT

53.28

EV to EBITDA

49.72

EV to Capital Employed

12.01

EV to Sales

17.18

PEG Ratio

Dividend Yield

0.15%

ROCE (Latest)

22.53%

ROE (Latest)

19.57%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

KST

Dow Theory

No Trend

Bullish

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2026

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 14 Schemes (5.47%)

FIIs

Held by 17 FIIs (1.81%)

Promoter with highest holding

Riva Resources Private Limited (40.35%)

Highest Public shareholder

Nuvama Crossover Opportunities Fund - Series Iii (2.95%)

Individual Investors Holdings

4.89%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 31.82% vs -11.20% in Mar 2026",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 31.28% vs -4.09% in Mar 2026",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "105.68",
          "val2": "80.17",
          "chgp": "31.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "39.19",
          "val2": "28.89",
          "chgp": "35.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.76",
          "val2": "1.97",
          "chgp": "-10.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "33.83",
          "val2": "25.77",
          "chgp": "31.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "37.08%",
          "val2": "36.04%",
          "chgp": "1.04%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "168.06",
          "val2": "168.40",
          "chgp": "-0.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "61.27",
          "val2": "60.03",
          "chgp": "2.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.47",
          "val2": "1.99",
          "chgp": "74.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "54.95",
          "val2": "41.98",
          "chgp": "30.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "36.46%",
          "val2": "35.65%",
          "chgp": "0.81%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "258.34",
          "val2": "251.88",
          "chgp": "2.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "90.88",
          "val2": "86.49",
          "chgp": "5.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.10",
          "val2": "3.24",
          "chgp": "26.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "81.82",
          "val2": "62.61",
          "chgp": "30.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "35.18%",
          "val2": "34.34%",
          "chgp": "0.84%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 27.94% vs 9.30% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 24.62% vs 4.16% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "642.26",
          "val2": "502.00",
          "chgp": "27.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "221.91",
          "val2": "189.95",
          "chgp": "16.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "7.60",
          "val2": "5.85",
          "chgp": "29.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "172.89",
          "val2": "138.73",
          "chgp": "24.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "34.55%",
          "val2": "37.84%",
          "chgp": "-3.29%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Jun'26 - QoQ

Jun'26

Mar'26

Change(%)

Net Sales

105.68

80.17

31.82%

Operating Profit (PBDIT) excl Other Income

39.19

28.89

35.65%

Interest

1.76

1.97

-10.66%

Exceptional Items

0.00

Standalone Net Profit

33.83

25.77

31.28%

Operating Profit Margin (Excl OI)

37.08%

36.04%

1.04%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2026 is 31.82% vs -11.20% in Mar 2026

Standalone Net Profit

QoQ Growth in quarter ended Jun 2026 is 31.28% vs -4.09% in Mar 2026

All Quarterly Results

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

168.06

168.40

-0.20%

Operating Profit (PBDIT) excl Other Income

61.27

60.03

2.07%

Interest

3.47

1.99

74.37%

Exceptional Items

0.00

Standalone Net Profit

54.95

41.98

30.90%

Operating Profit Margin (Excl OI)

36.46%

35.65%

0.81%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Half Yearly Results

Nine Monthly Results Snapshot (Standalone) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

258.34

251.88

2.56%

Operating Profit (PBDIT) excl Other Income

90.88

86.49

5.08%

Interest

4.10

3.24

26.54%

Exceptional Items

0.00

Standalone Net Profit

81.82

62.61

30.68%

Operating Profit Margin (Excl OI)

35.18%

34.34%

0.84%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Nine Monthly Results

Annual Results Snapshot (Consolidated) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

642.26

502.00

27.94%

Operating Profit (PBDIT) excl Other Income

221.91

189.95

16.83%

Interest

7.60

5.85

29.91%

Exceptional Items

0.00

Consolidate Net Profit

172.89

138.73

24.62%

Operating Profit Margin (Excl OI)

34.55%

37.84%

-3.29%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2026 is 27.94% vs 9.30% in Mar 2025

Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 24.62% vs 4.16% in Mar 2025

All Annual Results

Company CV

About Sudeep Pharma Ltd

Sudeep Pharma Ltd

Small Cap

Pharmaceuticals & Biotechnology

Sudeep Pharma Limited was incorporated as `Sudeep Pharma Private Limited' as a private limited company dated December 21, 1989, with the Registrar of Companies, Ahmedabad. Thereafter, Company was subsequently converted into a public limited company and the name of the Company was changed to `Sudeep Pharma Limited' pursuant to fresh certificate of incorporation dated October 21, 2024, issued by the Central Processing Centre.

Company Coordinates

No Company Details Available